AstraZeneca resumes COVID-19 vaccine trial
AstraZeneca announced that the Phase 3 trial of AZD1222 has been resumed following an adverse patient reaction.
Last week, the clinical trial evaluating AstraZeneca’s COVID-19 vaccine candidate AZD1222 was put on hold after a UK participant suffered a serious adverse reaction. The clinical trials, now in Phase 3, have been resumed after independent reviewers deemed it safe to do so.
“AstraZeneca and the University of Oxford, as the trial sponsor, cannot disclose further medical information,” AstraZeneca said in a statement. “All trial investigators and participants will be updated with the relevant information and this will be disclosed on global clinical registries, according to the clinical trial and regulatory standards.”
For more information, visit DrugTopics.com.
Contemporary OB/GYN Senior Editor Angie DeRosa gets insight on the current state of COVID-19 from Christina Han, MD, division director of maternal-fetal medicine at the University of California, Los Angeles, and member of its COVID-19 task force. Han is an active member of the Society for Maternal-Fetal Medicine and discusses the issues on behalf of SMFM.
Listen
Inactivated COVID-19 vaccines in pregnancy: No impact on neonatal outcome, study finds
November 28th 2023A comprehensive cohort study explored the impact of inactivated COVID-19 vaccines administered within 3 months before conception, revealing reassuring findings that neonatal outcomes, including preterm birth and NICU admission, remain unaffected.
Read More
